Global ADCs Market to grow at a CAGR of 41.58% during the period 2016 – 2020; Finds New Report

Report forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016 – 2020.

ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.

Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, products in the late pipeline stages will likely be launched during the forecast period. Some of these products include glembatumumab vedotin by Seattle Genetics, trastuzumab by Synthon Biopharmaceuticals, and SGN-35 by Takeda Pharmaceuticals. Some molecules are in the Phase I/II, preclinical, and discovery stages. ADCETRIS is currently under clinical trials for additional indications such as frontline mature T-cell lymphomas, B-cell lymphomas, and CD30-expressing conditions.

Further, the report states that the high developmental costs of antibody conjugates negatively impact the growth of the market.

Key players in the Global Antibody Drug Conjugates Market: F. Hoffmann-La Roche AG, Seattle Genetics Inc., and Takeda Pharmaceutical Company.

Other Prominent Vendors in the market are: AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, and Zymeworks.

Market driver

  • Robust late-stage pipeline
  • For a full, detailed list, view our report

Market challenge

  • High developmental costs
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Spanning over 75 pages Global Antibody Conjugates Drugs Market 2016 – 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Overview of ADCs, Pipeline portfolio, Market landscape, Market segmentation by MOA, Market segmentation by technologies used in ADCs, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://mrr.cm/Jqq

Find all Biotechnology report at: http://www.marketresearchreports.com/biotechnology

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Global Drugs for Chronic Cough Industry 2015 Market Report; Launched via MarketResearchReports.com

The Global Drugs for Chronic Cough Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Drugs for Chronic Cough industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Drugs for Chronic Cough market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.The Drugs for Chronic Cough industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 167 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Spanning over 154 pages Global Drugs for Chronic Cough Industry 2015 Market Research Report” report covers Industry Overview, Manufacturing Cost Structure Analysis of Drugs for Chronic Cough, Technical Data and Manufacturing Plants Analysis of Drugs for Chronic Cough, Production Analysis of Drugs for Chronic Cough by Regions, Type, and Applications, Consumption Volume and Consumption Value Analysis of Drugs for Chronic Cough by Regions, Analysis of Drugs for Chronic Cough Production, Supply, Sales and Market Status 2010-2015, Analysis of Drugs for Chronic Cough Industry Key Manufacturers, Price and Gross Margin Analysis of Drugs for Chronic Cough, Marketing Trader or Distributor Analysis of Drugs for Chronic Cough, Development Trend of Drugs for Chronic Cough Industry 2016-2021, Industry Chain Suppliers with Contact Information of Drugs for Chronic Cough, New Project Investment Feasibility Analysis of Drugs for Chronic Cough, Conclusion of the Europe Drugs for Chronic Cough Industry 2015 Market Research Report.

For more information Visit at: http://mrr.cm/oRz

Related Report:

Global Drugs for Cough Industry 2015 Market Research Report – visit at: http://mrr.cm/oRK

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Antibody-Drug Conjugates 2016: Perspectives & Opportunities – a Pipeline, Technology, Stakeholder & Business Analysis, New Report Launched

This report describes and analyzes the situation of antibody-drug conjugates as of November 2015 regarding:

  • ADC pipeline,
  • ADC technologies,
  • ADC stakeholders and
  • ADC business opportunities and commercial perspectives.

Although the initial enthusiasm about antibody-drug conjugates has made room for a more realistic understanding, the prospects for success of ADC drug candidates remain good and are based on a well-filled pipeline, increasing adoption of next generation ADC technologies, lessons learned from failures, a balanced mixture of stakeholders and a variety of options for funding of ADC developments. About 70 ADCs are in clinical and pre-IND stages of development and at least the same number of ADC programs are in preclinical R&D.

For the first time in 2015, combined sales of the approved and marketed ADC products Adcetris and Kadcyla will surpass the sales limit of US$ 1 billion. The pipeline of ADCs and immunoconjugates in advanced clinical development gives the chance of approval of further ADCs in the near- and mid-term future. The clinical attrition rate of ADCs is lower, i.e. better, than that of conventional, naked antibodies in oncology. The availability of next generation ADC technologies allows to select case by case the appropriate linker and payload. Site-specific conjugation technologies with and without engineering of the antibody generate homogenous products. Novel payloads provide the basis for enhanced antitumor activity. Prodrug concepts and polymeric carrier systems may not only contribute to a higher therapeutic index, but also boost efficacy by targeted delivery of a higher number of payloads than in conventional ADCs. Competition by ADCs directed against the same target is relatively low, except for clinically and commercially validated Her2 which is ideal to validate new technologies. However, targets are still a bottleneck with the attractive consequence that companies with successful target identification capabilities are highly rewarded by investors and business partners.

Nearly all major pharma and biotech companies have ADC programs, although with different strategies of how to gain access to ADC technologies. Few have established proprietary in-house capabilities, most still rely on outside technology providers. However, the duopoly of conventional ADC technology providers is converting into a more differentiated, heterogenous field of ADC technologies and technology providers.

This report entitled „Antibody-Drug Conjugates 2016: Perspectives & Opportunities – a Pipeline, Technology, Stakeholder & Business Analysis“ is based on the analysis of more than 90 companies, more than 100 ADC drug profiles and more than 26 ADC technologies and components. Sources of information are provided by 274 scientific references and numerous non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets (with hyperlinks leading to source of information). The report also describes and analyzes business deals in the ADC field, e.g. collaboration and license agreements, mergers and acquisitions, financial transactions (divestments, public offerings, private equity and venture capital fund-raising).

Coverage of this ADC report:

  • Next-to-market ADCs
  • ADC Drug Profiles: clinical, pre-IND, preclinical
  • Target Competition by ADCs
  • ADC Development Failures
  • Conventional & Emerging ADC Technologies
  • Polymeric ADC Carriers
  • Novel ADC Payloads & Linkers
  • Site-specific ADC Conjugation Technologies
  • Major Pharma & Biotech Companies with ADC Programs
  • Small and Medium Biopharmaceutical Companies with ADC Programs
  • Integrated ADC Technology & Pipeline Companies
  • Companies with Linker, Payload, Carrier and Conjugation Technologies
  • Commercial Opportunities and Perspectives with ADCs
  • Commericalization of Approved ADCs
  • Fund-Raising for ADC Companies
  • Pharma-Biotech & Biotech-Biotech Collaboration & Licensing Agreements

Spanning over 470 pages Antibody-Drug Conjugates 2016: Perspectives & Opportunities – a Pipeline, Technology, Stakeholder & Business Analysis” report covers Executive Summary, ADC Pipeline Analysis, ADC Technology Analysis, ADC Stakeholder Analysis, ADC Business Analysis, ADC Drug Profiles, ADC Company Profiles, References, ADDENDUM.

Find more information Visit at: http://mrr.cm/o6z

Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Huge Growth Opportunity in Indian Syringes and Needles Market by 2020, Reveals New Market Research Report by NOVONOUS

Syringes and needles market in India is expected to grow at a CAGR of 15% representing in huge opportunities in this sector, finds a new research report launched by NOVONOUS. This growth is driven by India’s large pool of patients, increasing healthcare expenditure, increasing healthcare awareness and rising government spending.

Syringes and needles market in India is dominated by disposable syringes and needles followed by AD syringes and needles, reusable syringes and needles and other syringes and needles (pre-filled, insulin etc.) based on the total revenue generated.

To know more about this newly launched market research report visit Syringes and Needles Market in India 2015-2020

Disposable syringes currently control the largest market share in terms of revenue in Indian syringes and needles market. As per NOVONOUS estimates, Indian disposable syringes market is expected to grow at a CAGR of 15% till 2020 and maintain its market share position even in 2020.

Auto Disable (AD)/ safety syringes and needles currently control the second largest market share in terms of revenue in Indian market. As per NOVONOUS estimates, Indian Auto Disable (AD)/ safety syringes and needles market is expected to grow at a CAGR of 19% till 2020 and maintain its market share position.

Reusable syringes and needles in Indian syringes and needles market is expected to grow at a CAGR of 5% till 2020.

Other (pre-filled, insulin etc.) syringes and needles in Indian syringes and needles market is expected to grow at a CAGR of 9% till 2020.

Spanning over 156 pages and 135 exhibits, “Syringes and Needles Market in India 2015-2020” report presents an in-depth assessment of the syringes and needles market from 2015 till 2020.

The report has detailed company profiles including their position in syringes and needles market value chain, financial performance analysis, product and service wise business strategy, SWOT analysis and key customer details for ten key players in Indian market namely Becton Dickinson India Pvt. Ltd., Lifelong Meditech Pvt. Ltd., Hindustan Syringe and Medical Devices Ltd., Veekay Surgicals Pvt. Ltd., Iscon Surgicals Ltd., M-Tech Meditrade Pvt. Ltd., Bio-Med Healthcare Products Pvt. Ltd., Needle Industries (India) Pvt. Ltd. (NIPL), Supertech Surgical Company and Albert David Ltd.

Scope of Syringes and Needles Market in India 2015 – 2020 report:

  • This report provides detailed information about Indian syringes and needles market including future forecasts.
  • This report identifies the need for focusing on syringes and needles sector.
  • This report provides detailed information on growth forecasts for overall Indian syringes and needles market up to 2020.
  • This report provides detailed information on segment wise (disposable syringes and needles, auto disable (AD)/ safety syringes and needles, reusable syringes and needles and other (pre-filled, insulin etc.) syringes and needles) growth forecasts for Indian syringes and needles market up to 2020.
  • The report identifies the growth drivers and inhibitors for Indian syringes and needles market.
  • This study also identifies various policies related to Indian syringes and needles market.
  • The report identifies various credit, policy and technical risks associated with Indian syringes and needles market.
  • This report has detailed profiles 10 key players in Indian syringes and needles market covering their business strategy, financial performance, future forecasts and SWOT analysis.
  • This report covers in details the competitive landscape in Indian syringes and needles market.
  • The report identifies EXIM scenario for syringes, suture needles, tubular metal needles, hollow needles, other tubular metal needles, catheters (For urine, stool), cardiac Catheters and cannulae in India.
  • The report identifies top countries exporting syringes, suture needles, tubular metal needles, hollow needles, other tubular metal needles, catheters (For urine, stool), cardiac Catheters and cannulae to India.
  • The report identifies top countries importing syringes, suture needles, tubular metal needles, hollow needles, other tubular metal needles, catheters (For urine, stool), cardiac Catheters and cannulae from India.
  • This report identifies key industry bodies and associations and their role in Indian syringes and needles market.
  • This report provides PESTLE (political, economic, social, technological, legal and environmental) analysis for Indian syringes and needles market.
  • This report provides Porter’s Five Forces analysis for Indian syringes and needles market.
  • This report provides SWOT (strengths, weakness, opportunities and threats) analysis for Indian syringes and needles market.
  • This report identifies the key challenges faced by new players in Indian syringes and needles market.
  • This report provides future trends and opportunities for Indian syringes and needles market.
  • This report also provides strategic recommendations for policy makers, end users, service providers and investors.

For more information and purchase this report please visit:

http://www.marketresearchreports.com/novonous/syringes-and-needles-market-india-2015-2020

To browse more market research reports by NOVONOUS visit:

http://www.marketresearchreports.com/publisher/novonous

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

About NOVONOUS

NOVONOUS helps organizations differentiate themselves, break entry barriers, track investments, develop strategies and see through corporate fog by providing business intelligence that works for their business. For more information about NOVONOUS visit: http://www.novonous.com

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions

Global Opioid-Induced Constipation Market To Grow at a CAGR of 30.18% over the period 2014-2019; Finds New Report

Report forecast the global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.

Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.

This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs.

On the basis of the mechanism of action of drugs, the market is grouped into the following categories:

  • Peripherally Acting Mu-opioid Receptor Antagonist
  • Locally Acting Chloride Channel Activator
  • Others

On the basis of the route of administration of drugs, the market is grouped into the following categories:

  • Oral
  • Parenteral

On the basis of the dosage form of drugs, the market is grouped into the following categories:

  • Solid
  • Liquid

According to the report, the low levels of awareness about opioid-induced constipation among patients and the medical fraternity have resulted in the usage of off-label and OTC medications as the treatment options. However, these drugs are only partially successful in treating this condition. The entry of peripherally acting mu-opioid receptor antagonists such as Movantik/Moventig has driven the market significantly. The drug targets the underlying cause of opioid-induced constipation without affecting the analgesic action of the opioid drugs. Therefore, this is increasingly becoming the preferred treatment option for opioid-induced constipation.

Further, the report states that the availability of OTC and off-label drugs restricts the market growth.

Global Opioid-induced Constipation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Global Opioid-Induced Constipation Market: AstraZeneca, Takeda Pharmaceutical and Valeant Pharmaceuticals International

Other Prominent Vendors in the market are: Abbott, Bayer, Boehringer Ingelheim, C.B. Fleet, Cosmo Pharmaceuticals, Daewoong, Daiichi Sankyo, GlaxoSmithKline, Ironwood Pharmaceuticals, Johnson & Johnson, Merck, Mundipharma, Nektar Therapeutics, Pfizer, Progenics Pharmaceuticals, Shionogi, SLA Pharma, Sucampo, Synergy Pharmaceuticals and Theravance

Key Regions

  • Americas
  • APAC
  • EMEA

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Availability of OTC and Off-label Drugs
  • For a full, detailed list, view our report

Market Trend

  • Shift to Targeted Therapy
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Spanning over 69 pages and 23 Exhibits Global Opioid-Induced Constipation Market 2015-2019” report covers Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Product Profiles, Disease Overview, Pipeline Portfolio, Market Landscape, Market Segmentation by Mechanism of Action, Market Segmentation by Route of Administration, Market Segmentation by Dosage Form, Geographical Segmentation, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and their I.act, Vendor Landscape, Key Vendor Analysis.

For further information on this report, please visit- http://mrr.cm/4a9

Other Report:

1st Hard Adventure Equipment Market in the US 2015-2019 – See more at – http://mrr.cm/4at

Find all Drug Delivery Reports at: http://www.marketresearchreports.com/drug-delivery

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Asthma Drugs Market in the US to grow at a CAGR of 4.64% over the period 2014-2019; Finds New Report

Report forecast the asthma drugs market in the US to grow at a CAGR of 4.64% over the period 2014-2019.

Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.

This report covers the present scenario and the growth prospects of the asthma drugs market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sale of various classes of drugs used to treat asthma, which include:

  • Bronchodilators
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Immunosuppressants
  • Combination of LABA/ICS

According to the report, pharmaceutical companies are developing drugs that have a better safety and efficacy profile than those already available in the market. These drugs are undergoing clinical trials or are awaiting approval by regulatory agencies. For instance, NVA237 by Novartis and Mepolizumab by GlaxoSmithKline are among the most promising drugs for the treatment of asthma. Mepolizumab by GlaxoSmithKline was submitted for approval as a maintenance treatment for severe eosinophilic asthma to the US Food and Drug Administration (FDA) in November 2014. Tralokinumab by AstraZeneca is another promising molecule, which is under phase III clinical trials.

Further, the report states that the unknown etiology of the condition makes it difficult for pharmaceutical companies to develop a curative drug for the treatment of asthma.

Asthma Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the asthma drugs market in the US: AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline and Merck

Other Prominent Vendors in the market are: Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy’s Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals and Valeant Pharmaceuticals

Market driver

  • Rise in disease prevalence
  • For a full, detailed list, view our report

Market challenge

  • Unknown disease etiology
  • For a full, detailed list, view our report

Market trend

  • Popularity of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Spanning over 103 pages and 49 Exhibits Asthma Drugs Market in the US 2015-2019” report covers Executive Summary, List of Abbreviations, Scope of the Report, Market Research Methodology, Introduction, Disease Overview, Pipeline Portfolio, Market Landscape, Market Segmentation by Class of Drug, Bronchodilators, Combination of LABA/ICS, Immunosuppressants, Leukotriene Antagonists, Mast Cell Stabilizers, Buying Criteria, Market Growth Drivers, Drivers and their Impact, Market Challenges, Impact of Drivers and Challenges, Market Trends, Trends and Their Impact, Vendor Landscape, Key Vendor Analysis.

For further information on this report, please visit- http://mrr.cm/42V

Find all Drug Delivery Reports at: http://www.marketresearchreports.com/drug-delivery

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Global Transdermal Drug Delivery Market to 2020, New Report Launched

Global Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation

“GLOBAL & USA TRANSDERMAL DRUG DELIVERY MARKET TO 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation” by Kelly Scientific Publications is a dedicated report on the transdermal drug delivery industry and its impact on the USA and global markets.

This comprehensive report tackles problems that this vertical growing market faces and evaluates saturated sub-markets. A detailed outlay of its major players is performed including business strategy and future development analysis, merger and acquisition tactics, current product and pipeline entry evaluation and a detailed section on each player’s financial situation. This analysis determines the unmet needs of the transdermal drug delivery industry and specific niche areas of market entry.

The transdermal drug delivery market has substantial associations within the smoking cessation market, analgesics/pain market, generics market, neuropathic pain market and also the women’s health market. In the future it will enter the vaccine and gene therapy markets. Transdermal drug delivery is a complex area that has many driving factors including the unmet need for non-invasive drug delivery systems for pediatric, geriatric and dementia patients.

This report describes the current technologies that are propelling the market space and emerging trials and pipeline agents that will make a significant impact on the industry. It examines the current transdermal delivery systems and how generic competition is allowing penetration of new players in the market and saturation of niche areas.

Financial figures of the drug delivery market and the transdermal drug delivery space are revealed in this report. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial, business strategy and product review of key players in the transdermal drug delivery industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the transdermal drug delivery market has huge opportunities for growth in the areas of dementia (Alzheimer’s & Parkinson’s Disease), generics, paediatrics and geriatrics. Currently the USA is the most prominent market place, followed by Europe, Asia and Emerging Markets. This report will reveal in-depth analysis of the industry and provide cutting-edge intelligence on the current and future spaces it will penetrate.

In 2014, the global drug delivery market (DDM) was worth just under $x billion, a significant jump from $x billion in 2010. The market grew steadily within this time period with a compound annual growth interest of x%. By the end of 2016, it is expected to be worth over $x billion, and make gains to over $x billion by 2020.

Today the US market holds just over x% share, and within the next five years Asian and Emerging market spaces will increase in size. By 2020, the Asian drug delivery market will surge past x%, compared to over x% in Europe. The US total drug delivery market will continue to maintain its x% share by 2020.

Within the total drug delivery market exists the advanced DDM, which is further segmented into the following niche areas:

  • Transdermal
  • Transmucosal
  • Targeted
  • Sustained-released agents
  • Prodrugs
  • Implants
  • Intrauterine devices
  • Oral

Targeted drug delivery is the most significant player within this space, and generated $x billion globally in 2014. Currently, targeted drug delivery systems are indicated in specific cancers, diabetes, tuberculosis and also cardiovascular disorders. These ‘nanocarriers’ are forecast to propel the advanced drug delivery space by an estimated $x million by 2021.

This report is presented as follows:

  • By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)
  • By Geography (Global, USA)
  • By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)
  • By Sub-market (Generics, Women’s Health, Analgesics, Neuropathic Pain)

A wealth of financial data & business strategy information is provided including:

  • Up-to-date company financials, sales & revenue figures
  • Revenue and market forecasts
  • Business model strategies for drug delivery, pharmaceutical and biotechnology companies
  • Comprehensive account of company products, financials & portfolios

SWOT, Economic & Regulatory Environment specifics include:

  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Technologies driving the market (e.g., chemical enhancers, microneedles)
  • Top fastest growing market segments and emerging opportunities
  • Top pharmaceutical companies within the market
  • Comprehensive product portfolios, R&D activity and pipeline products
  • M&A activity and future strategies of top companies
  • High demand and unmet need enhances the market
  • Challenges of the transdermal drug delivery market

Who should read this report?

  • Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
  • Industry professionals and business strategists will discover key information to propel their policies
  • Investors will gain inside information to dominant players in the industry and future forecasts
  • Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment C-Suite professionals, Decision Makers, Business Development professionals

This report will tell you if the companies mentioned are:

  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity

Benefits of Investing in our Cutting-Edge Reports:

  • Clients receive complementary content* with mid-level and enterprise wide licences.
  • Post-sale complementary consultation with senior expert analyst is included.
  • Use of tables and figures in your own reports and presentations is permitted.
  • Each report provides straight-talking strategic analysis & sector intelligence.
  • All reports are updated each quarter to give you the most up-to-date information.

Spanning over 280 pages, Global Transdermal Drug Delivery Market to 2020” report covering the Executive Summary, Transdermal Drug Delivery, Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery, Transdermal Drug Delivery Technologies, How Nanotechnology is Transforming Transdermal Drug Delivery, Transdermal Drug Delivery and Disease States. The report covered companies are – 3M, AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp), Actavis, Actelion, Ascend Therapeutics, Bayer, Boehringer Ingelheim, Endo International, GlaxoSmithKline, Hercon Pharmaceutical, Janssen Pharmaceuticals

For further information on this report, please visit- http://mrr.cm/4T4

Find all Drug Delivery Reports at: http://www.marketresearchreports.com/drug-delivery

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

The Global Pre-Filled Syringe Market to 2024, New Report Launched

The Global Pre-filled Syringe Market 2014-2024 report analyses how this important sub-sector will continue to grow across the next decade. The report highlights key companies, geographies and products that we believe will deliver double digit growth across the next decade.

Buy this report today and acquire analysis of the state of the pre-filled syringes market in 2014 and a market forecastfor the period 2014-2024. Market forecasts are also provided for global pre-filled syringes for glass and plastics on the global level (value and volume) as well as for the geographic regions of key pre-filled syringe types (value and volume).

The advantages that will drive the growth of pre-filled syringes include ease of administration, improved safety, reduced risk of contamination, elimination of medication errors, low incidence of needlestick injuries, accurate dosing and reduction in medical expenditure due to reduced visits to healthcare facilities.

When compared to standard injectables, the pre-filled syringes market is still evolving, and its use is slowly increasing. Developed countries have shown a strong adoption rate for pre-filled syringes whereas developing & ROW countries have often been slow in adopting this technology. During the forecast period, however, the adoption rate will witness a healthy growth in emerging markets, and will witness a growth rate above that of developed geographies such as the US and in Europe.

The market is highly consolidated and is currently dominated by key global players such as Abbott Labs, Becton Dickinson, Baxter, Nipro Corporation, Schott, Gerresheimer, West Pharmaceutical, Ypsomed, Bespak and Unilife Corporation. Other companies such as Haselmeier; Weigao Group, Nuova Ompi (Stevanato Group), Owen Mumford and Vetter Pharma are likely to foster innovation in the coming years.

The Global Pre-filled Syringe Market 2014-2024 report includes over 125 tables, charts and graphs quantifying and forecasting the market in detail. In addition, the report offers 14 profiles of the leading PFS companies in the market alongside 3 expert interviewees offering key insights into the state of the market currently and in the future;

Schott Kaisa

West Pharmaceuticals

Fresenius Kabi

Spanning over 160 pages, The Global Pre-Filled Syringe Market to 2024” report covering the Executive Summary, Introduction to the Pre Filled Syringe Market, Global Pre-Filled Syringe; Market Revenue and Volume Forecasts to 2024, Key Geographies in the Global Pre-Filled Syringe Market 2014-2024, Leading Therapeutic Segments for Pre-Filled Syringes 2013-2024, SWOT Analysis of the Global Pre-Filled Syringes Market 2014-2024, Company Profiles, Expert Opinion. The report covered companies are – Abbott Labs, AbbVie, Aesica, AesRX LLC (Part of Baxter International), Amgen, Antares Pharma Inc., Bausch, Baxter, Bayer, Becton Dickinson, Berlin-Chemie, Biocon, Biogen Idec, Biogen Inc., Biosensors International Group, BMS

For further information on this report, please visit- http://mrr.cm/45M

Find all Medical Devices Reports at:

http://www.marketresearchreports.com/medical-devices

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

The Global Erythropoietin (EPO) Drugs market Expeceted to reach $11.9 billion by 2020, Finds New Report

According to a new report “Global Erythropoietin (EPO) Drugs Market (Type, Application and Geography) – Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013-2020“, forecasts the Global EPO market to reach $11.9 billion by 2020, with promising CAGR of 9.7% from 2014 to 2020. Darbepoetin alfa is fastest growing drug class at a CAGR of 12.9% during the forecast period, owing to its high potency and minimal side-effects.

Rising incidences of Cancer, ESRD (End Stage Renal Disease), and HIV have largely contributed to the overwhelming demand for EPO drugs. Approximately 20% of the patients suffering from Cancer/HIV and ~70% of the patients suffering from ESRD undergo chemotherapy, which induces anemia in such patients, requiring EPO treatment. Despite this, the market nevertheless witnesses restraints due to highly priced EPO drugs resulting in minimal adoption. However, commercialization of EPO biosimilars would eventually ease the influence of restraints and fuel the market growth, primarily across the developing regions.Globally, ~70% of the market share is held by the developed regions owing to favorable reimbursements leading to affordability for EPO drugs. Going forward, owing to commercialization of EPO biosimilars, the Asia-Pacific EPO drugs market would be the most potential market among other regions.

Key findings of the study:

Europe led the global EPO drug market in 2013 closely followed by North America

Asia Pacific EPO drugs market is projected to grow at a CAGR of 13.3% during the forecast period, fastest among the four geographies

Currently, Anemia therapeutics (Cancer and HIV treatment) market leads the overall EPO drugs market; however, kidney therapeutic segment would emerge as the largest market segment by 2020

Originator companies are investing in R&D for expanding product i.e. EPO drug applications to newer disorders such as neural diseases and in wound healing

EPO drugs market is witnessing high commercialization of biosimilars for the ‘off-patent’ drug namely Erythropoietin alfa

The first EPO drug – Epogen (Erythropoietin alfa), launched by Amgen, has witnessed patent expiry in 2014. Following this, a number of biosimilar Erythropoietin alfa have been launched by major companies such as Biocon, Ranbaxy, Emcure Pharmaceuticals. In addition, Amgen currently owns the patent Aranesp for Darbepoetin alfa; which is expected to expire by 2016, thus, calling for launch of Darbepoetin alfa biosimilars. Some of leading players operating in EPO drug market are Amgen Inc., Johnson & Johnson, Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.

For further information on this report, please visit- http://mrr.cm/4iz

Find all Drug Delivery Reports at: http://www.marketresearchreports.com/drug-delivery

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Global Transdermal Drug Delivery Market to 2017, New Report Launched

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables & figures over 280 pages.

This report is presented as follows:

  • By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO)
  • By Geography (Global, USA)
  • By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)
  • By Sub-market (Generics, Women’s Health, Analgesics, Neuropathic Pain)

A wealth of financial data & business strategy information is provided including:

  • Up-to-date company financials, sales & revenue figures
  • Revenue and market forecasts
  • Business model strategies for drug delivery, pharmaceutical and biotechnology companies
  • Comprehensive account of company products, financials & portfolios

SWOT, Economic & Regulatory Environment specifics include:

  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Technologies driving the market (e.g., chemical enhancers, microneedles)
  • Top fastest growing market segments and emerging opportunities
  • Top pharmaceutical companies within the market
  • Comprehensive product portfolios, R&D activity and pipeline products
  • M&A activity and future strategies of top companies
  • High demand and unmet need enhances the market
  • Challenges of the transdermal drug delivery market

Who should read this report?

  • Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
  • Industry professionals and business strategists will discover key information to propel their policies
  • Investors will gain inside information to dominant players in the industry and future forecasts
  • Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment C-Suite professionals, Decision Makers, Business Development professionals

This report will tell you if the companies mentioned are:

  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity

This detailed report is supported with 320 figures and tables over 280 pages and profiles the main pharmacos in the transdermal drug delivery market.

Benefits of Investing in our Cutting-Edge Reports:

  • Clients receive complementary content* with mid-level and enterprise wide licences.
  • Post-sale complementary consultation with senior expert analyst is included.
  • Use of tables and figures in your own reports and presentations is permitted.
  • Each report provides straight-talking strategic analysis & sector intelligence.
  • All reports are updated each quarter to give you the most up-to-date information.

Spanning over 280 pages, Global Transdermal Drug Delivery Market to 2017” report covering the Executive Summary, Transdermal Drug Delivery, Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery, Transdermal Drug Delivery Technologies, How Nanotechnology is Transforming Transdermal Drug Delivery, Transdermal Drug Delivery and Disease States, Gene Therapy and Transdermal Drug Delivery, Vaccines and Transdermal Drug Technology, Global Drug Delivery Market, Transdermal Drug Delivery Company Business Profiles and Strategic Evaluation, Transdermal Drug Delivery Company Financial Analysis, Current Transdermal Drug Delivery Products on the Market, In-Depth SWOT Analysis of the Transdermal Drug Delivery Market. The report covered 23 companies are – 3M, AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp), Actavis, Actelion, Ascend Therapeutics, Bayer, Boehringer Ingelheim, Endo International, GlaxoSmithKline, Hercon Pharmaceutical, Janssen Pharmaceuticals, Kremers Urban Pharmaceuticals, Mylan Pharmaceuticals, Nitto Denko, Novartis, Noven Pharmaceuticals, ParPharm, ProStrakan, Shire, Teikoku USA, Teva Pharmaceutical Industries, UCB, Upsher-Smith.

For more information see – http://mrr.cm/44Z

Find all Drug Delivery Reports at: http://www.marketresearchreports.com/drug-delivery

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.